Investment
Matrix Partners China participated in NeuShen Therapeutics' $80M+ Series B round alongside B Capital, Legend Capital, TruMed Investment and SSCI, with existing shareholder Lilly Asia Ventures increasing its stake. NeuShen is a CNS biotech company.
NeuShen Therapeutics